Predicting the extent of heterogeneity in meta-analysis, using empirical data from the Cochrane Database of Systematic Reviews

被引:558
作者
Turner, Rebecca M. [1 ]
Davey, Jonathan [1 ]
Clarke, Mike J. [2 ]
Thompson, Simon G. [3 ]
Higgins, Julian P. T. [1 ]
机构
[1] MRC, Biostat Unit, Inst Publ Hlth, Cambridge CB2 0SR, England
[2] Queens Univ Belfast, Ctr Publ Hlth, All Ireland Hub Trials Methodol Res, Belfast BT7 1NN, Antrim, North Ireland
[3] Univ Cambridge, Dept Publ Hlth & Primary Care, Cambridge, England
基金
英国医学研究理事会;
关键词
Meta-analysis; heterogeneity; intervention studies; Bayesian analysis; TRIALS;
D O I
10.1093/ije/dys041
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background Many meta-analyses contain only a small number of studies, which makes it difficult to estimate the extent of between-study heterogeneity. Bayesian meta-analysis allows incorporation of external evidence on heterogeneity, and offers advantages over conventional random-effects meta-analysis. To assist in this, we provide empirical evidence on the likely extent of heterogeneity in particular areas of health care. Methods Our analyses included 14 886 meta-analyses from the Cochrane Database of Systematic Reviews. We classified each meta-analysis according to the type of outcome, type of intervention comparison and medical specialty. By modelling the study data from all meta-analyses simultaneously, using the log odds ratio scale, we investigated the impact of meta-analysis characteristics on the underlying between-study heterogeneity variance. Predictive distributions were obtained for the heterogeneity expected in future meta-analyses. Results Between-study heterogeneity variances for meta-analyses in which the outcome was all-cause mortality were found to be on average 17% (95% CI 10-26) of variances for other outcomes. In meta-analyses comparing two active pharmacological interventions, heterogeneity was on average 75% (95% CI 58-95) of variances for non-pharmacological interventions. Meta-analysis size was found to have only a small effect on heterogeneity. Predictive distributions are presented for nine different settings, defined by type of outcome and type of intervention comparison. For example, for a planned meta-analysis comparing a pharmacological intervention against placebo or control with a subjectively measured outcome, the predictive distribution for heterogeneity is a log-normal (-2.13, 1.58(2)) distribution, which has a median value of 0.12. In an example of meta-analysis of six studies, incorporating external evidence led to a smaller heterogeneity estimate and a narrower confidence interval for the combined intervention effect. Conclusions Meta-analysis characteristics were strongly associated with the degree of between-study heterogeneity, and predictive distributions for heterogeneity differed substantially across settings. The informative priors provided will be very beneficial in future meta-analyses including few studies.
引用
收藏
页码:818 / 827
页数:10
相关论文
共 24 条
[1]   The interpretation of random-effects meta-analysis in decision models [J].
Ades, AE ;
Lu, G ;
Higgins, JPT .
MEDICAL DECISION MAKING, 2005, 25 (06) :646-654
[2]  
[Anonymous], COCHRANE DATABASE SY
[3]  
[Anonymous], THESIS U BRISTOL
[4]  
[Anonymous], HLTH RES CLASS SYST
[5]  
[Anonymous], NICE TAX SUBJ ENC SC
[6]  
[Anonymous], COCHRANE DATABASE SY
[7]  
[Anonymous], HLTH OUTC RES PRIM
[8]   Characteristics of meta-analyses and their component studies in the Cochrane Database of Systematic Reviews: a cross-sectional, descriptive analysis [J].
Davey, Jonathan ;
Turner, Rebecca M. ;
Clarke, Mike J. ;
Higgins, Julian P. T. .
BMC MEDICAL RESEARCH METHODOLOGY, 2011, 11
[9]   METAANALYSIS IN CLINICAL-TRIALS [J].
DERSIMONIAN, R ;
LAIRD, N .
CONTROLLED CLINICAL TRIALS, 1986, 7 (03) :177-188
[10]  
Higgins J., 2009, Cochrane Handbook for Systematic Reviews of Interventions, DOI DOI 10.1002/9780470712184.CH8